Sirtex gets hammered on failed cancer study

Shares of Australia's Sirtex Medical were slammed hard after the biotech reported that its liver cancer therapy failed a closely watched clinical study. The biotech had been hoping to offer data proving that its SIR-Spheres treatment should be used as a frontline treatment for cancer rather than in last-ditch efforts. But investigators tried to salvage something with data indicating an effect on tumors in the liver. Story